Dexamethasone dose and length of hospital stay among hospitalized COVID-19 patients: a retrospective cross-sectional study in Malaysia

Simple item page
dc.contributor.authorOthman, N. S.en_US
dc.contributor.authorMohd Taufek, N. H.en_US
dc.contributor.authorJamaluddin, W. A.en_US
dc.contributor.authorZin, C. S.en_US
dc.date.accessioned2024-09-24T06:55:07Z
dc.date.available2024-09-24T06:55:07Z
dc.date.issued2023-11
dc.description.abstractBackground: Dexamethasone is a potent corticosteroid that has been widely used as COVID-19 treatment. However, optimal dose of dexamethasone in COVID-19 treatment and how its different doses affect the patient outcomes is uncertain. This retrospective study aimed to evaluate the use of dexamethasone dose and length of hospital stay in COVID-19 patients admitted to two public hospitals in the east coast region of Malaysia between February 2020 and August 2021. Methods: This study included all hospitalized patients who were receiving dexamethasone during the study period. Dexamethasone doses were categorized into high dose (?15 mg/day), moderate dose (7-14 mg/day) and low dose (?6 mg/day). A multivariable logistic regression was conducted to evaluate the potential risk factors associated with length of hospital stays. Results: Of 119 patients enrolled, majority (40%) of patients received high dose dexamethasone, followed by 33% received moderate dose and 27% received low dose. Patients who received high doses were associated with extended hospital stays of 4-5 days and more frequently required mechanical ventilation. Multivariable logistic regression showed that elderly (OR=1.03; 95% CI=1.00-1.06, p=0.001) and severe stage of COVID-19 (stage 4-stage 5) upon hospital admission (OR=2.79; 95% CI=1.17-6.68, p=0.021) increased the risk of prolonged hospital stay. Conclusions: COVID-19 patients treated with high and moderate doses of dexamethasone were associated with longer hospital stay and required mechanical ventilation compared to those on low doses. Future studies are needed to provide more evidence on benefits of low dexamethasone dose in COVID-19 patients.en_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang, Malaysiaen_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang, Malaysiaen_US
dc.identifier.affiliationsDepartment of Multidisciplinary, Hospital Hulu Terengganu, Terengganu, Malaysiaen_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang, Malaysiaen_US
dc.identifier.citationOthman N. S., Mohd Taufek N. H., Jamaluddin W. A., Zin C. S.. Dexamethasone dose and length of hospital stay among hospitalized COVID-19 patients: a retrospective cross-sectional study in Malaysia. International Journal of Community Medicine and Public Health. 2023 Nov; 10(11): 4053-4061en_US
dc.identifier.issn2394-6032
dc.identifier.issn2394-6040
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/227551
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber11en_US
dc.relation.volume10en_US
dc.source.urihttps://doi.org/10.18203/2394-6040.ijcmph20233429en_US
dc.subjectCOVID-19en_US
dc.subjectDexamethasoneen_US
dc.subjectOutcomesen_US
dc.subjectMalaysiaen_US
dc.titleDexamethasone dose and length of hospital stay among hospitalized COVID-19 patients: a retrospective cross-sectional study in Malaysiaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijcmph2023v10n11p4053.pdf
Size:
684.87 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Community Medicine and Public Health